Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process.

Chungnam National University, Daejeon, Republic of Korea.
European Journal of Pharmaceutics and Biopharmaceutics (Impact Factor: 3.83). 07/2008; 69(2):454-65. DOI: 10.1016/j.ejpb.2008.01.007
Source: PubMed

ABSTRACT In this work, amorphous atorvastatin calcium nanoparticles were successfully prepared using the supercritical antisolvent (SAS) process. The effect of process variables on particle size and distribution of atorvastatin calcium during particle formation was investigated. Solid state characterization, solubility, intrinsic dissolution, powder dissolution studies and pharmacokinetic study in rats were performed. Spherical particles with mean particle size ranging between 152 and 863 nm were obtained by varying process parameters such as precipitation vessel pressure and temperature, drug solution concentration and feed rate ratio of CO2/drug solution. XRD, TGA, FT-IR, FT-Raman, NMR and HPLC analysis indicated that atorvastatin calcium existed as anhydrous amorphous form and no degradation occurred after SAS process. When compared with crystalline form (unprocessed drug), amorphous atorvastatin calcium nanoparticles were of better performance in solubility and intrinsic dissolution rate, resulting in higher solubility and faster dissolution rate. In addition, intrinsic dissolution rate showed a good correlation with the solubility. The dissolution rates of amorphous atorvastatin calcium nanoparticles were highly increased in comparison with unprocessed drug by the enhancement of intrinsic dissolution rate and the reduction of particle size resulting in an increased specific surface area. The absorption of atorvastatin calcium after oral administration of amorphous atorvastatin calcium nanoparticles to rats was markedly increased.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to improve the solubility, stability and bioavailability of amorphous atorvastatin calcium (AT) by complexing it with hydroxypropyl-beta-cyclodextrin. The formation of the inclusion complexation was identified by molecular modeling, phase solubility diagrams, differential scanning calorimetry and X-ray powder diffractometry. Orally Disintegrating Tablets (ODT) were then manufactured by direct compression. Apart from improved stability compared to pure AT, disintegration time of 27s, hardness of 5 kg and favorable mouth feel were achieved. In vitro dissolution tests of the ODT of AT inclusion complex exhibited higher dissolution rates than those with pure drug and the commercial tablet Lipitor. In vivo bioavailability studies in rats also showed shorter T(max), higher C(max) and increased AUC of 4.42 and 1.86 fold compared to the plain drug ODT and Lipitor. These results strongly suggest to use HP-beta-CD to improve the physicochemical characteristics and bioavailability of AT.
    Pharmazie 01/2012; 67(1):46-53. · 0.96 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study is to improve the dissolution characteristics of a poorly water-soluble drug glibenclamide (GLB), by preparing nanoparticles through liquid anti solvent precipitation. A Plackett–Burman screening design was employed to screen the significant formulation and process variables. A total of 12 experiments were generated by Minitab® 16 for screening 5 independent variables namely the amount of poloxamer 188 (PX) (X1), amount of PVP S 630 D (PD) (X2), solvent to antisolvent volume ratio (S/AS) (X3), amount of GLB (X4) and speed of mixing (X5). Mean particle size (Y1), saturation solubility (Y2) and % dissolution efficiency (%DE5min) (Y3) were selected as response variables. All the regression models yielded a good fit with high determination coefficient and F value. The Pareto chart depicted that all the independent variables except the amount of GLB had a significant effect (p < 0.001) on the response variables. The mathematical model for mean particle size (PS) generated from the regression analysis was given by PS = 830 − 8.14 PX + 12.8 PD − 11.1 S/AS + 1.42 GLB Conc. − 0.676 speed of mixing (R2 = 93.5, Fratio = 17.28, p < 0.001). Prepared GLB nanoparticles exemplified a significant improvement (p < 0.05) in the release as compared to pure GLB with the optimum formulation releasing almost 80% drug within first 5 min. The X-ray diffraction studies concluded that the crystallinity of nanoparticles from the optimum batch was intact and the increased dissolution could be ascribed to conversion of unmilled GLB to nanoparticles.
    Powder Technology. 235:405–411.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The objective of the study was to prepare amorphous atorvastatin hemi-calcium using spray-drying and supercritical antisolvent (SAS) process and evaluate its physicochemical properties and oral bioavailability. Atorvastatin hemi-calcium trihydrate was transformed to anhydrous amorphous form by spray-drying and SAS process. With the SAS process, the mean particle size and the specific surface area of amorphous atorvastatin were drastically changed to 68.7+/-15.8nm, 120.35+/-1.40m2/g and 95.7+/-12.2nm, 79.78+/-0.93m2/g from an acetone solution and a tetrahydrofuran solution, respectively and appeared to be associated with better performance in apparent solubility, dissolution and pharmacokinetic studies, compared with unprocessed crystalline atorvastatin. Oral AUC0-8h values in SD rats for crystalline and amorphous atorvastatin were as follow: 1121.4+/-212.0ngh/mL for crystalline atorvastatin, 3249.5+/-406.4ngh/mL and 3016.1+/-200.3ngh/mL for amorphous atorvastatin from an acetone solution and a tetrahydrofuran solution with SAS process, 2227.8+/-274.5 and 2099.9+/-339.2ngh/mL for amorphous atorvastatin from acetone and tetrahydrofuran with spray-drying. The AUCs of all amorphous atorvastatin significantly increased (P<0.05) compared with crystalline atorvastatin, suggesting that the enhanced bioavailability was attributed to amorphous nature and particle size reduction. In addition, the SAS process exhibits better bioavailability than spray-drying because of particle size reduction with narrow particle size distribution. It was concluded that physicochemical properties and bioavailability of crystalline atorvastatin could be improved by physical modification such as particle size reduction and generation of amorphous state using spray-drying and SAS process. Further, SAS process was a powerful methodology for improving the physicochemical properties and bioavailability of atorvastatin.
    International Journal of Pharmaceutics 08/2008; 359(1-2):211-9. · 3.99 Impact Factor


Available from